Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.57 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6303017 | 0.94 | CHRNA7 (0.66) | CHRNA7NAAAKMT2AMEN1USP30 | |
| SCHEMBL6303021 | 0.94 | CHRNA7 (0.66) | CHRNA7NAAAKMT2AMEN1USP30 | |
| SCHEMBL6310543 | 0.91 | CHRNA7 (0.51) | CHRNA7NAAAUSP30GRM5MMP13 | |
| SCHEMBL6304901 | 0.90 | CHRNA7 (0.57) | CHRNA7NAAAUSP30MMP2MMP13 | |
| SCHEMBL6306964 | 0.90 | CHRNA7 (0.54) | CHRNA7NAAAKMT2AMEN1GRM5 | |
| SCHEMBL6303369 | 0.89 | CHRNA7 (0.58) | CHRNA7NAAAUSP30MMP2MMP13 | |
| SCHEMBL6303278 | 0.89 | USP30 (0.61) | CHRNA7KMT2AMEN1USP30MMP2 | |
| SCHEMBL6305737 | 0.88 | CHRNA7 (0.57) | CHRNA7USP30MMP2MMP13 | |
| SCHEMBL6309895 | 0.88 | CHRNA7 (0.75) | CHRNA7KMT2AMEN1USP30MMP2 | |
| SCHEMBL6304732 | 0.88 | CHRNA7 (0.57) | CHRNA7KMT2AMEN1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852716-B2 | Substituted-aryl compounds for treatment of disease | PFIZER INC (US) | 2005-02-08 | — | — | US | claimed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-6852716-B2 | Substituted-aryl compounds for treatment of disease | PFIZER INC (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | NAT1, CYP7A1, CYP7B1 | CHRNA7 2937/4885NAAA 2942/4885KMT2A 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.